price month
posit caspian data small cell lung cancer
rais potenti broad imfinzi success
morn astrazeneca announc interim analysi
caspian studi show overal surviv os benefit
imfinzi chemo line extens stage sclc see posit
surpris studi receiv littl investor attent follow
fail mystic studi cs pharmavalu forecast assum
probabl caspian npv
expect full data septemb expect full data
caspian present world lung sept barcelona
caspian also includ treme imfinzi arm continu final
analysi appar superior imfinzi mono vs imfinzi treme mirror
detail analysi mystic studi could explain treme
ad efficaci addit toxic therefor limit
treatment durat activ arm investor broadli dismiss treme
within az immuno-oncolog strategi see littl impact
competit landscap roch tecentriq alreadi approv set
follow posit interim data esmo mrk
keytruda trial expect report decemb
differ caspian hinder cross-
trial comparison detail key differ essenti
control arm receiv intens theray caspian vs
mean efficaci activ arm broadli compar
studi hazard ratio vs control favour
caspian allow carboplatin cisplatin vs carboplatin
caspian control arm cycl chemo vs cycl
caspian recruit extensive-stag patient vs also
caspian allow prophylact cranial irradi control arm vs
allow pci control activ
beyond direct benefit caspian view today news
revitalis interest long tail imfinzi studi follow
fail mystic studi investor limit expect az
immuno-oncolog franchis currently-approv pacif set stage
unresect lung cancer azn rich catalyst stream
studi due report offer potenti
significantli extend scope imfinzi franchis figur set
key readout includ pharmavalu npv expect probability-
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
adjust npv increment imfinzi indic azn npv
flex prob would add azn pharmavalu npv
sale probabl success npv
poseidon imfinzi chemo imfinzi treme chemo vs chemo nsclc
comer readout due cse prob success sale
assumpt imfimzi chemo combo line competit npv
sale probabl success npv
probabl success npv
pearl asia trial imfinzi mono vs chemo nsclc readout due
submiss
probabl success npv
pacif stage chemoradi imfinzi given concurr
complet jan cse sale probabl success npv
background small cell lung cancer
sclc aggress fast-grow tumour metastas rapidli
repres lung cancer
sclc occur almost exclus smoker
new case sclc diagnos year europ
us
third sclc
diagnosi equival patient patient us
receiv first-lin therapi
recent posit data tecentriq fda-approv standard care
sclc platinum-bas chemotherapi plu etoposid nccn also
overal surviv rate extens stage sclc
figur roch estim sclc market
compani mention price
trung huynh domin lunn jo walton matthew weston phd certifi respect compani secur individu
analyz view express report accur reflect person view subject compani secur
part compens directli indirectli relat specif recommend view express
price rate histori astrazeneca azn
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less attract
underperform least attract invest opportun octob canadian well european ra ting base stock total
return rel analyst coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun latin american asia stock exclud japan
australia rate base stock total return rel averag total return relev countri egion benchmark india bse sensex
prior octob canadian rate base stock absolut total return potenti current share price rel
attract stock total return potenti within analyst coverag univers australian ew zealand stock expect total return
calcul includ roll dividend yield outperform rate assign greater equal under-perform wh ere
less equal neutral may assign overlap rate rang allow analyst assign rate
put context associ risk prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest
view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least past
month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cov er multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform ost close
